{"id":"NCT03036150","sponsor":"AstraZeneca","briefTitle":"A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease","officialTitle":"A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-02-02","primaryCompletion":"2020-06-12","completion":"2020-06-12","firstPosted":"2017-01-30","resultsPosted":"2021-07-07","lastUpdate":"2021-07-07"},"enrollment":4304,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Forxiga TM","Farxiga TM"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease.","primaryOutcome":{"measure":"Time to the First Occurrence of Any of the Components of the Composite: â‰¥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death.","timeFrame":"Up to 38.2 months","effectByArm":[{"arm":"Dapagliflozin","deltaMin":197,"sd":null},{"arm":"Placebo","deltaMin":312,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":390,"countries":["United States","Argentina","Brazil","Canada","China","Denmark","Germany","Hungary","India","Japan","Mexico","Peru","Philippines","Poland","Russia","South Korea","Spain","Sweden","Ukraine","United Kingdom","Vietnam"]},"refs":{"pmids":["40679863","40658498","40526444","39475817","38770818","38580424","38564654","38320128","38097862","37876229","37872654","37119064","37103935","37071317","36469914","36414316","36323444","35977807","35497805","35445820","34619108","34619106","34446370","34183431","33338413","33186054","32970396","32862232","32778748","32559465","31939531"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169AC00001&amp;attachmentIdentifier=c59c2c03-ebfa-46f4-beac-d0b14b62db99&amp;fileName=d169ac00001_csp_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169AC00001&amp;attachmentIdentifier=987ded9e-acd7-4718-a380-431a2b2d1377&amp;fileName=d169ac00001_sap_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":633,"n":2149},"commonTop":["Nasopharyngitis","Urinary tract infection","Hypoglycaemia","Hypertension","Oedema peripheral"]}}